Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Replimune GroupFRA:7R8 +9.22%27 Net Current Asset Value is €0.56 as of Jun. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 928 Biotechnology companies, Replimune Group ranks worse than 87.93% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Replimune Group's net current asset value per share for the quarter that ended in Jun. 2026 was €0.56.
The historical rank and industry rank for Replimune Group's Net Current Asset Value or its related term are showing as below:
FRA:7R8'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.41 Med: 2.97 Max: 22.99
Current: 22.85
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Replimune Group was 22.99. The lowest was 1.41. And the median was 2.97.
FRA:7R8's Price-to-Net-Current-Asset-Value is ranked worse than 87.93% of 928
companies
in the Biotechnology industry
Industry Median: 4.82
vs FRA:7R8: 22.85
Replimune Group (FRA:7R8) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Replimune Group Net Current Asset Value Related Terms
Replimune Group Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Replimune Group's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7R8 vs ANNX, SLDB, ABUS: Net Current Asset Value Comparison
For the Biotechnology subindustry, Replimune Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Replimune Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.56 mean?
Replimune Group (FRA:7R8) has a Net Current Asset Value of €0.56 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #816 out of 928 companies in the Biotechnology industry, placing it in the top 87.9%.
Is Replimune Group's Net Current Asset Value too high?
Replimune Group's current Net Current Asset Value is €0.56. Based on the distribution chart, Replimune Group ranks #816 out of 928 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Net Current Asset Value compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #816 out of 928 companies for Net Current Asset Value. This places Replimune Group in the lower half of its industry. The industry median Net Current Asset Value is 4.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.82, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Replimune Group and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Net Current Asset Value is €0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current Net Current Asset Value of €0.56. The current Net Current Asset Value is €0.56. Replimune Group's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current Net Current Asset Value is €0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
27GF Score
Get the complete analysis for FRA:7R8
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7R8 has been successfully added to your 
